Breaking News
Why Dual Engine Failure Changes Everything -- Louisville Crash Update
Transforming Storage Shelf / Workbench - Small Space Organization
Our 3-Step Strategy for a Stress-Free Pantry
BEHIND THE DEEP STATE | The War on Farms
Top Tech News
HUGE 32kWh LiFePO4 DIY Battery w/ 628Ah Cells! 90 Minute Build
What Has Bitcoin Become 17 Years After Satoshi Nakamoto Published The Whitepaper?
Japan just injected artificial blood into a human. No blood type needed. No refrigeration.
The 6 Best LLM Tools To Run Models Locally
Testing My First Sodium-Ion Solar Battery
A man once paralyzed from the waist down now stands on his own, not with machines or wires,...
Review: Thumb-sized thermal camera turns your phone into a smart tool
Army To Bring Nuclear Microreactors To Its Bases By 2028
Nissan Says It's On Track For Solid-State Batteries That Double EV Range By 2028
Carbon based computers that run on iron
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.